Gilead Sciences | GILD - Pre Tax Profit

Stock Price
152.50
Daily Change
3.13 2.10%
Monthly
22.64%
Yearly
58.79%
Q1 Forecast
137.58

Gilead Sciences reported $2.43B in Pre-Tax Profit for its fiscal quarter ending in June of 2025.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
ALKERMES USD 100.74M 4.1M Sep/2025
Alnylam Pharmaceuticals USD 238.97M 274.33M Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
Biogen USD 557.3M 186.7M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Eli Lilly USD 7.23B 456M Sep/2025
Gilead Sciences USD 2.43B 780M Jun/2025
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Glaxosmithkline GBP 2.46B 569M Sep/2025
Incyte USD 482.31M 75.7M Sep/2025
J&J USD 4.97B 2.53B Dec/2025
Merck USD 6.74B 22M Sep/2025
Moderna USD -187M 631M Sep/2025
Neurocrine Biosciences USD 291.8M 132.3M Sep/2025
Novartis USD 4.2B 335M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
PTC Therapeutics USD -23.07M 47.98M Sep/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Sanofi EUR -1.16B 5.5B Dec/2025
Sarepta Therapeutics USD -194.05M 347.69M Sep/2025
United Therapeutics USD 438M 29.6M Sep/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025